NDA 021437 · Upjohn
Inspra
Eplerenone · Oral · Aldosterone Antagonist
NovelLast checked: Nov 20, 2026Latest source record: Jun 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Sep 27, 2002
Approved uses
3
Original approval plus efficacy supplements
Registered trials
137
24 Phase 3, 11 recruiting
FAERS reports
13,077
11,339 serious, 1,274 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 23, 2025.
INSPRA is an aldosterone antagonist indicated for: • Improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) • The treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction INSPRA is indicated to improve survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (≤40%) (HFrEF) after an acute myocardial infarction (MI). 1.2 Hypertension INSPRA is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood...
Mechanism: Eplerenone binds to the mineralocorticoid receptor and blocks the binding of aldosterone, a component of the renin-angiotensin-aldosterone-system (RAAS). Aldosterone synthesis, which occurs primarily in the adrenal gland, is modulated by multiple factors, including angiotensin II and non-RAAS mediators such as adrenocorticotropic hormone (ACTH) and potassium. Aldosterone binds to mineralocorticoid receptors in both epithelial (e.g., kidney) and nonepithelial (e.g., heart, blood vessels, and brain) tissues and increases blood pressure through induction of sodium reabsorption and possibly other...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 31, 2008 Supplement 5 · Efficacy LabelPediatric Written RequestPediatric Amendment 1
- Oct 7, 2003 Supplement 2 · Efficacy · priority review LetterLabelReview
- Sep 27, 2002 Original approval · Type 1 - New Molecular Entity NovelLabelReviewLetter
3 products under this application
- INSPRA · EPLERENONE 100MG · TABLET, ORAL · Discontinued
- INSPRA · EPLERENONE 25MG · TABLET, ORAL · Prescription · TE AB
- INSPRA · EPLERENONE 50MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Eplerenone" as an intervention, any sponsor and status, largest first.
- A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart FailurePivotal-lookingEnrolling by invitation
Bispebjerg HospitalAcademic, hospital or other
NCT03984591 · 7,200 participants (planned) · Start Nov 1, 2020 · Primary completion Dec 31, 2028
Drug: Eplerenone; Spironolactone · For: Systolic Heart Failure
Sites: Copenhagen, Denmark
- A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure MedicinesPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00232180 · 2,743 participants · Start Mar 2006 · Primary completion May 2010
Drug: Eplerenone · For: Heart Failure
Sites: Phoenix, Arizona; Loma Linda, California; Merced, California · 307 sites in all
- Optimal Medical Treatment of Difficult-to-treat HypertensionPivotal-lookingStatus unknown
National Institute of Cardiology, Warsaw, PolandAcademic, hospital or other
NCT06275763 · 2,500 participants (planned) · Start Oct 20, 2023 · Primary completion Dec 1, 2025
Drug: Phase C: Eplerenone; Phase C: Spironolactone and 2 more · For: Hypertension
Sites: Warsaw, Poland
- Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection FractionPivotal-lookingRecruiting
Uppsala UniversityAcademic, hospital or other
NCT02901184 · 2,000 participants (planned) · Start Nov 23, 2017 · Primary completion Dec 2026
Drug: Spironolactone · For: Heart Failure With Preserved Ejection Fraction
Sites: Alexander City, Alabama; Birmingham, Alabama; Tucson, Arizona · 78 sites in all
- HFrEF Polypill in Sri Lanka RCTPivotal-lookingRecruiting
Washington University School of MedicineAcademic, hospital or other
NCT07569640 · 1,672 participants (planned) · Start Aug 17, 2026 · Primary completion Apr 2029
Drug: HFrEF Polypill · For: Heart Failure With Reduced Ejection Fraction
Sites: Kandy, Sri Lanka; Anuradhapura, Sri Lanka; Kurunegala, Sri Lanka · 12 sites in all
- Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)Pivotal-lookingCompleted
Vifor Pharma, Inc.Industry
NCT03888066 · 1,195 participants · Start Apr 24, 2019 · Primary completion Sep 2, 2021
Drug: Patiromer; Placebos · For: Hyperkalemia
Sites: Alexander City, Alabama; Huntsville, Alabama; Phoenix, Arizona · 415 sites in all
BayerBayer (BAYRY)
NCT01807221 · 1,066 participants · Start Jun 17, 2013 · Primary completion Nov 11, 2014
Drug: Finerenone (BAY94-8862); Placebo and 1 more · For: Heart Failure
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 172 sites in all
- Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial InfarctionPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT01176968 · 1,012 participants · Start Sep 2010 · Primary completion Oct 2012
Drug: Eplerenone; Placebo · For: Myocardial Infarction
Sites: Edmonton, Canada; Vancouver, Canada; St. John's, Canada · 75 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea1,162
- acute kidney injury984
- cardiac failure969
- hypotension896
- fatigue701
- dizziness688
- diarrhoea597
- drug interaction550
- oedema peripheral537
- drug ineffective524
- nausea516
- off label use502
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 41 |
| 2005 | 56 |
| 2006 | 63 |
| 2007 | 72 |
| 2008 | 114 |
| 2009 | 128 |
| 2010 | 148 |
| 2011 | 263 |
| 2012 | 320 |
| 2013 | 272 |
| 2014 | 326 |
| 2015 | 456 |
| 2016 | 553 |
| 2017 | 626 |
| 2018 | 790 |
| 2019 | 1,000 |
| 2020 | 1,212 |
| 2021 | 1,240 |
| 2022 | 1,176 |
| 2023 | 1,045 |
| 2024 | 1,133 |
| 2025 | 1,111 |
| 2026 | 932 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Inspra (Eplerenone)
2024 spending
$349K
Beneficiaries
66
253 claims
Per beneficiary
$5,281
$13.28 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $683,246 |
| 2021 | $532,310 |
| 2022 | $414,402 |
| 2023 | $369,294 |
| 2024 | $348,565 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.
Provenzano M, Puchades MJ, Garofalo C, et al. · J Am Soc Nephrol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.
Jhund PS, Talebi A, Henderson AD, et al. · Lancet 2024 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Eplerenone in patients with systolic heart failure and mild symptoms.
Zannad F, McMurray JJ, Krum H, et al. · N Engl J Med 2011 · Multicenter Study, Randomized Controlled Trial
- Eplerenone for hypertension.
Tam TS, Wu MH, Masson SC, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis.
Elshahat A, Mansour A, Ellabban M, et al. · BMC Cardiovasc Disord 2024 · Systematic Review, Meta-Analysis
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Filippatos G, Anker SD, Böhm M, et al. · Eur Heart J 2016 · Randomized Controlled Trial
Sponsor: Upjohn
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.